Related Experiment Videos
Avoidance of red blood cell transfusion in an extremely preterm infant given recombinant human erythropoietin therapy
1Department of Paediatrics, Monash Medical Centre, Melbourne, Victoria, Australia.
Insights
Recombinant human erythropoietin (rHuEPO) successfully managed anemia in a premature infant of Jehovah's Witnesses, minimizing blood transfusions. The treatment supported hemoglobin levels during critical care, including ventilation and treatment for intraventricular hemorrhage.
Area of Science:
- Neonatal Medicine
- Hematology
- Pharmacology
Background:
- Premature infants, especially those born at 26 weeks gestation, are at high risk for anemia.
- Jehovah's Witnesses' religious beliefs preclude blood transfusions, necessitating alternative anemia management strategies.
- This infant required extensive medical support, including ventilation and treatment for intraventricular hemorrhage and periventricular leucomalacia.
Observation:
- An infant born at 26 weeks gestation with severe prematurity and multiple complications (hyaline membrane disease, intraventricular hemorrhage, periventricular leucomalacia) required intensive care.
- The infant received a regimen of intravenous and subcutaneous rHuEPO, supplemented with vitamins and iron, to manage anemia.
- Blood sampling was minimized through consistent non-invasive monitoring, limiting blood loss to 21 mL.
Findings:
- The rHuEPO therapy regimen, alongside minimized blood sampling, effectively prevented the need for red blood cell transfusions.
- Hemoglobin levels were maintained above critical thresholds throughout the infant's hospital stay and showed improvement at follow-up.
- The infant was discharged with stable hematological parameters and continued to show adequate hemoglobin levels at 3 and 6 months postnatally.
Implications:
- This case demonstrates the successful application of rHuEPO therapy in managing anemia in extremely preterm infants, particularly in situations where blood transfusions are contraindicated.
- Minimizing blood sampling in neonatal intensive care units is crucial for reducing iatrogenic anemia and improving patient outcomes.
- Further research into optimized rHuEPO dosing and combination therapies may enhance anemia management in vulnerable preterm populations.
Abstract:
To avoid red blood cell (RBC) transfusions, recombinant human erythropoietin (rHuEPO) was given to an infant born at a gestation of 26 weeks and a birthweight of 830 g to parents who were Jehovah's Witnesses. The infant had hyaline membrane disease and required 52 days of assisted ventilation and 19 days of oxygen therapy. He received theophylline therapy for 61 days for recurrent apnoea and bradycardia. He developed bilateral intraventricular haemorrhage (IVH) and left-sided periventricular leucomalacia (PVL). Intravenous rHuEPO was started on day 1 at 200 U/kg per day for 1 month followed by subcutaneous rHuEPO 400 U/kg three times a week for 6 more weeks, supplemented with Vitamin E, folic acid and iron. Blood sampling was kept to a minimum and non-invasive blood-gas monitoring was used consistently. Consequently, the estimated cumulative volume of blood loss from sampling was only 21 mL during his hospital stay. His haemoglobin (Hb) was 150 g/L at birth and this fell to below 100 g/L from day 25 onwards. His lowest leucocyte count was 3.6 x 10(9)/L. He was discharged on day 83 with a Hb of 95 g/L, Hct of 29%, reticulocyte count of 2.8% and weight of 2400 g. At a postnatal age of 3 months, he had a Hb of 113 g/L. At 6 months, investigations showed: Hb 121 g/L, haematocrit 33%, reticulocyte 1% and a weight of 4.4 kg. He was readmitted to hospital once for an episode of vomiting and follow up to date showed developmental delay.(ABSTRACT TRUNCATED AT 250 WORDS)